RNPC3 and glioblastoma: Using RNP-IP, we showed that ATO treatment significantly decreased the quantity of AGO2 bound to SESN2 mRNA in S1 GBM cells, suggesting that AGO2-mediated mRNA degradation was suppressed by ATO (Figure 3A).